Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin (IVMB0423)
- SKU:
- IVMB0423
Frequently bought together:
Description
| Product Name: | Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin |
| SKU: | IVMB0423 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | KW-0761 |
| Target: | CD194 |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | Depletion |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Muted |
| Synonyms: | Mogamulizumab, CD194, CCR4 |
| Product Concentration: | 0.5 mg/ml |
| Immunogen: | Humanization of mouse anti-CCR4 mAb7. |
| Applications and Recommended Usage: | FC The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA |
| Antigen Distribution: | CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL). |
| Formulation: | This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only. |
| Additional Applications Reported In Literature: | FA |
| Additional Reported Applications For Relevant Conjugates: | Depletion |
Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This biotinylated antibody is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
Mogamulizumab (Anti-CD194 / CCR4) Biosimilar In Vivo Antibody
€249 - €6,779
Mogamulizumab (Anti-CD194 / CCR4) Biosimilar In Vivo Antibody (Fc Reduced)
€579